Augmentation of Zinc Concentration in Blood has a Favorable Effect on Cardiac Function Post-Myocardial Infarction

Background: We have recently reported that polaprezinc which is a zinc delivery has an anti-inflammatory effect and improves cardiac function after acute myocardial infarction (AMI). As a secondary analysis, the aim of the present study was to evaluate if zinc concentration in blood affects anti-inflammatory effect and cardiac function after AMI. Methods: The primary study population included 50 patients with AMI. We equally divided the patients into two groups between the high group (H) and the low group (L) by blood concentration of zinc without relating to polaprezinc medication. The two groups were analyzed about cardiac function, cardiac enzymes, and the levels of the inflammation marker interleukin-6 (IL-6) as similar to the primary study. Results: The urine zinc levels of the H group were prominently higher than those of the L group at 8 days after PCI. The mean IL-6 level was strongly reduced in the H group (44.7(7.15-107.7) pg/mL vs. 130(19.6-384.25) pg/mL, respectively; p<0.05). As for the days of decline of both CRP and WBC, there were significant differences between the two groups (Figure 2). In addition, echocardiography indicated that the EF of the H group was clearly increased between day 3 and 9 months post-MI (54.5(50.5-59.75)% vs. 62(55-70)%, respectively; p<0.01). Conclusions: The present study suggests that high concentration of zinc has an anti-inflammatory effect and improves cardiac function after AMI.